You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • FRI0176 Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite dmard therapy: 52-week results of clinical, radiographic and pharmacokinetic assessm…

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – anti-TNF therapy
FRI0176 Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite dmard therapy: 52-week results of clinical, radiographic and pharmacokinetic assessments

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Takeuchi T, Harigai M, Tanaka Y, et al
FRI0176 Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite dmard therapy: 52-week results of clinical, radiographic and pharmacokinetic assessments
Annals of the Rheumatic Diseases 2013;71:371.